Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.

The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.

Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ET

Dial In:

A replay of the conference call will be available for 7 days following the conclusion of the call:

An accompanying slide presentation will be embedded in the webcast (live and replay) and can be accessed under the ‘Company Events’ section of the Applied DNA investor relations website at https://investors.adnas.com/news-events/company-events/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid (“DNA”). Using the polymerase chain reaction (“PCR”) to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase (“RNAP”) for use in the production of mRNA therapeutics; and, (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.

Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.

For additional information:

Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com

Web: https://investors.adnas.com/

SOURCE: Applied DNA Sciences, Inc.

View the original press release on accesswire.com

Staff

Recent Posts

PrimeBiome— How PrimeBiome Gummies Boost Glowing Skin With Bacillus Coagulans & Babchi

Clinically-Inspired Supplement PrimeBiome Gains Momentum in 2025 as Consumers Report Radiant Skin, Improved Gut Health,…

20 hours ago

Lipozem Reviews (BUYER ALERT!) Is It Legit And Safe To Use? Consumer Report On Reddit Breaks It Down!

MIAMI, April 12, 2025 (GLOBE NEWSWIRE) -- The Lipozem weight loss supplement has been garnering…

20 hours ago

Kane Biotech Announces New Agreement with Outside the Box Capital Inc.

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG,…

20 hours ago

TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2024 Financial Results on April 14, 2025

FREDERICK, Md., April 11, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ),…

20 hours ago

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ:…

20 hours ago

Ontario’s Measles Outbreak Requires Much More Visible & Effective Public Health Response

TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- The Ontario Health Coalition is raising concerns about…

20 hours ago